All Stories

  1. Landiolol in patients with supraventricular arrhythmias: real-world efficacy and safety
  2. New Cardioprotective Frontiers in Double Inhibition With SGLT2 and PCSK9 in Cancer Survivors
  3. Early predictors of carotid atherosclerosis in patients with type 2 diabetes mellitus
  4. Astrocyte-derived exosomes captured with amyloid-β42 and BACE-1 proteins as a promising biomarker for cognitive impairment in hypertensive patients
  5. Nrf2/ARE pathway agonist omaveloxolone attenuates adverse cardiac remodeling in pressure-induced cardiac dysfunction
  6. Carbohydrate antigen 125: promising diagnostic biomarker in heart failure with preserved ejection fraction
  7. Digital health interventions for cardiac rehabilitation in stable coronary artery disease
  8. Low Levels of Adropin Predicted New Incidents of Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction
  9. The Association of Adropin with Asymptomatic Coronary Calcification in Patients in Early Stages of Chronic Kidney Disease
  10. Metabolic Dysregulation of Hydrogen Sulfide as a Driver of Vascular Disease
  11. Macrophage migration inhibitory factor (MIF): can functional insights pave the way for future therapeutics in cardiovascular diseases?
  12. The Association of Adropin with Asymptomatic Coronary Calcification in Patients with Early Stages of Chronic Kidney Disease
  13. Low levels of adropin are associated with acute kidney injury after decongestion in patients with acutely decompensated heart failure
  14. Nutritional and immune-inflammatory indexes in risk stratification of heart failure with preserved ejection fraction
  15. Serum Levels of Irisin Are Positively Associated with Improved Cardiac Function in Patients with Heart Failure with Reduced Ejection Fraction
  16. Cognitive Impairment in Acute Decompensated Heart Failure
  17. SEX DISPARITIES IN LONG-TERM CARDIOVASCULAR OUTCOMES IN COVID-19 DISCHARGE DURING ALPHA, DELTA AND OMICRON WAVES
  18. Liquid Biopsy Biomarkers for Personalized Management in Heart Failure
  19. Regenerative Therapy with Extracellular Vesicles in Acute and Chronic Kidney Injury
  20. On MANTA vascular closure devices following veno arterial extracorporeal membrane oxygenation: Effectiveness and complications
  21. Multifactorial management of complex comorbidity followed by heart failure, chronic kidney disease and type 2 diabetes mellitus: the way to overcome missed opportunities
  22. Predictive value of the systemic immune inflammation index in recurrence of atrial fibrillation after radiofrequency catheter ablation
  23. Protective activity of adipose-derived stem cell extracellular vesicles in ischemia and/or reperfusion
  24. Irisin Predicts Poor Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Low Levels of N-Terminal Pro-B-Type Natriuretic Peptide
  25. Deterioration of endothelial function as a risk factor for osteoporosis in patients with type 2 diabetes mellitus and MAFLD
  26. Predictors of Poor Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Low Levels of N-Terminal Pro-B-Type Natriuretic Peptide
  27. Predictors for Irreversibility of Contrast-Induced Acute Kidney Injury in Patients with Obesity After Contrast-Enhanced Computed Tomography Coronary Angiography
  28. Sex Differences in Long-Term Cardiovascular Outcomes and Mortality After COVID-19 Hospitalization During Alpha, Delta and Omicron Waves
  29. Circulating Cell-Free Nuclear DNA Predicted an Improvement of Systolic Left Ventricular Function in Individuals with Chronic Heart Failure with Reduced Ejection Fraction
  30. The Silent Threat: A Retrospective Cohort Study on the Impact of Prediabetes on ST-Elevation Myocardial Infarction Survival—A Call to Action!
  31. The Silent Threat: Prediabetes and Its Impact on Heart Attack Survival—A Call to Action!
  32. Circulating Cell-Free Nuclear DNAs Predicted an Improvement of Systolic Left Ventricular Function in Individuals with Chronic Heart Failure with Reduced Ejection Fraction
  33. Low Levels of Adropin Predict Adverse Clinical Outcomes in Outpatients with Newly Diagnosed Prediabetes after Acute Myocardial Infarction
  34. Trajectory of Irisin as a Predictor of Kidney-Related Outcomes in Patients with Asymptomatic Heart Failure
  35. Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides
  36. An overview of circulating and urinary biomarkers capable of predicting the transition of acute kidney injury to chronic kidney disease
  37. Implementation of risk-based lipid-lowering therapies in older (age ≥ 65 years) and very-old adults (age ≥ 75 years) with ischemic heart disease in the greater Salzburg region
  38. Circulating Levels of erythrocytes-derived vesicles are associated with glucose control in type 2 diabetes mellitus patients with atrial fibrillation
  39. Predictors of worsening kidney function and their relation to SGLT2 inhibitor dapagliflozin administration in type 2 diabetes mellitus patients with chronic heart failure
  40. Natural bioactive ingredients as plausible anti-atherosclerotic agent: evidence and hope from calycosin
  41. Potential harm of midodrine in renal failure patients with concomitant heart failure with reduced ejection fraction
  42. Low serum irisin levels predicted newly atrial fibrillation in patients with any phenotypes of chronic heart failure
  43. Circulating levels of erythrocytes-derived vesicles related to poor glycaemia control in type 2 diabetes mellitus patients with atrial fibrillation
  44. PREDICTORS OF KIDNEY EVENTS IN TYPE 2 DIABETES MELLITUS PATIENTS WITH CHRONIC HEART FAILURE PATIENTS
  45. Methods to predict heart failure in diabetes patients
  46. Low irisin levels predict acutely decompensated heart failure in type 2 diabetes mellitus patients
  47. Variable effect of exercise training programme on cardiovascular outcomes in high-genetic-risk individuals with diabetes
  48. Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases
  49. Extracellular vesicles in heart failure
  50. Diagnostic and predictive abilities of myokines in patients with heart failure
  51. The Plausible Role of Vascular Adhesion Molecules in Cardiovascular Diseases
  52. Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery
  53. Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure
  54. The effect of sglt-2 inhibitor dapagliflozin on adropin serum levels in patients with chronic heart failure and concomitant type 2 diabetes mellitus
  55. Early beta-blocker therapy improves in-hospital mortality of patients with non-ST-segment elevation myocardial infarction – a meta-analysis
  56. Cell-free DNA as a plausible biomarker of chronic kidney disease
  57. Missed Opportunities in Implementation and Optimization of Lipid-Lowering Therapies in Very-High-Risk Patients Presenting with ST-Segment Elevation Myocardial Infarction
  58. Myokine profile and glycemic control in type 2 diabetes mellitus patients with heart failure
  59. DAPAGLIFLOZIN MODULATES ADROPIN SERUM LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC HEART FAILURE
  60. DECREASED SERUM LEVELS OF IRISIN PREDICTED HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
  61. IMPROVEMENT OF PREDICTIVE UTILITY OF NATRIURETIC PEPTIDE FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH APELIN IN TYPE 2 DIABETES MELLITUS PATIENTS
  62. CAUSES OF AN UNFRIENDLY CLINICAL OUTCOME OF MYOCARDIAL INFARCTION AGGRAVATED BY CARDIOGENIC SHOCK: A SINGLE-CENTER RETROSPECTIVE STUDY
  63. Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion
  64. Editorial for the Special Issue “Biological Markers of Cardiovascular Diseases: Applications and Utility in Clinical Practice”
  65. Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure
  66. Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure
  67. Cardiac Hepatopathy: New Perspectives on Old Problems through a Prism of Endogenous Metabolic Regulations by Hepatokines
  68. Lower Circulating Cell-Free Mitochondrial DNA Is Associated with Heart Failure in Type 2 Diabetes Mellitus Patients
  69. The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure
  70. Cardiac Reprogramming with Stem Cells: An Advanced Therapeutic Strategy in Advanced Heart Failure
  71. Regeneration des Herzens auf der Grundlage von Stammzellen: Gibt es einen Platz für Optimismus in der Zukunft?
  72. Pericarditis - Diagnosis and Management Challenges [Working Title]
  73. Myeloperoxidase and global longitudinal strain in prognostication of clinical events after ST segment elevation myocardial infarction
  74. Biomarkers in Heart Failure: From Research to Clinical Practice
  75. EFFECTIVENESS OF ADDITION OF METFORMIN TO STATIN THERAPY FOR PRODIABETOGENIC CHANGES CORRECTION IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY
  76. Interplay between Myokine Profile and Glycemic Control in Type 2 Diabetes Mellitus Patients with Heart Failure
  77. Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus
  78. Interview: Alexander E Berezin
  79. Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus
  80. The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
  81. Circulating levels of irisin and apelin predict heart failure with preserved ejection fraction in type 2 diabetes mellitus patients
  82. UTILITY OF IRISIN AND APELIN IN PREDICTION OF HEART FAILURE PHENOTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS
  83. Point-of-care heart failure platform: where are we now and where are we going to?
  84. Sodium-Glucose Co-transporter-2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Breakthrough in Improvement of Clinical Outcomes?
  85. Serum Levels of Irisin Predict Cumulative Clinical Outcomes in Heart Failure Patients With Type 2 Diabetes Mellitus
  86. Elevated levels of apelin predict favorable clinical course of heart failure in type 2 diabetes mellitus patients
  87. Predictive value of both irisin and apelin for heart failure with preserved ejection fraction in type 2 diabetes mellitus patients
  88. Severe Aortic Valve Stenosis and Pulmonary Hypertension: A Systematic Review of Non-Invasive Ways of Risk Stratification, Especially in Patients Undergoing Transcatheter Aortic Valve Replacement
  89. Extracellular Vesicles and Thrombogenicity in Atrial Fibrillation
  90. Discriminative Utility of Apelin-to-NT-Pro-Brain Natriuretic Peptide Ratio for Heart Failure with Preserved Ejection Fraction among Type 2 Diabetes Mellitus Patients
  91. Vascular Functional Recovery and Reparation by Human Endothelial Progenitor Cells
  92. Vascular Functional Recovery and Reparation by Human Endothelial Progenitor Cells
  93. Reversibility of adverse cardiac remodeling in type 2 diabetes mellitus patients: focus on sodium-glucose cotransporter-2 inhibitors
  94. Heart failure among patients with prediabetes and type 2 diabetes mellitus: diagnostic and predictive biomarkers: a narrative review
  95. Biomarker-Based Guideline-Directed Medical Therapy of Heart Failure: The Gap Between Guidelines and Clinical Practice
  96. Biomarker-Based Guideline-Directed Medical Therapy of Heart Failure: The Gap Between Guidelines and Clinical Practice
  97. Low ratio of serum levels of apelin and NT-pro-BRAIN natriuretic peptide predicted the development of heart failure with preserved ejection fraction among type 2 diabetes mellitus patients
  98. Challenging and opportunities in clinical implementation of circulating cardiac biomarkers in diabetes mellitus: the narrative review
  99. Heart Failure and Diabetes Mellitus: Biomarkers in Risk Stratification and Prognostication
  100. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium–glucose co-transporter 2 inhibitors?
  101. Promising Novel Biomarkers in Cardiovascular Diseases
  102. Antigen-presenting cell-derived extracellular vesicles in accelerating atherosclerosis
  103. Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes
  104. Stem-Cell-Based Cardiac Regeneration: Is There a Place For Optimism in the Future?
  105. The Hormone-like Myokines Irisin as Novel Biomarker for Cardiovascular Risk Stratification”,
  106. The Diagnostic and Therapeutic Value of Multimarker Analysis in Heart Failure. An Approach to Biomarker-Targeted Therapy
  107. Serendipity and thinking outside the box in cardiovascular research
  108. Emerging Role of Adipocyte Dysfunction in Inducing Heart Failure Among Obese Patients With Prediabetes and Known Diabetes Mellitus
  109. The role of single nucleotide polymorphism of val66met (rs6265) of the brain-derived neurotropic factor in formation of endpoints after st-segment elevation myocardial infarction
  110. Subclinical emotional distress predicts 6-month clinical outcomes after ST-segment elevation myocardial infarction
  111. Brain-derived neurotrophic factor gene polymorphism in post-ST-elevation myocardial infarction patients undergoing primary percutaneous intervention
  112. Факторы неблагоприятного клинического исхода инфаркта миокарда, осложненного кардиогенным шоком: результаты одноцентрового ретроспективного исследования
  113. Endothelial cell-derived extracellular vesicles in atherosclerosis: the emerging value for diagnosis, risk stratification and prognostication
  114. Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers
  115. The Utility of New Biomarker-based Predictive Model for Clinical Outcomes Among ST-elevation Myocardial Infarction Patients
  116. The predictive value of vascular endothelial growth factor-A gene polymorphism for clinical outcomes among acute ST-segment elevation myocardial infarction patients: A single center prospective study
  117. Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review
  118. Extracellular Endothelial Cell-Derived Vesicles: Emerging Role in Cardiac and Vascular Remodeling in Heart Failure
  119. Altered adipocytokine profile predicts early stage of left ventricular remodeling in hypertensive patients with type 2 diabetes mellitus
  120. Diagnostic and therapeutic value of micro-RNAs in inflammatory bowel disease
  121. Emerging role of natriuretic peptides in diabetes mellitus: New approaches for risk stratification
  122. Emerging diagnostic and predictive utilities of natriuretic peptides in diabetes mellitus patients at high cardiovascular risk
  123. Efficacy of fixed dose of triple combination of perindopril-indapamide-amlodipine in obese patients with moderate-to-severe arterial hypertension: an open-label 6-month study
  124. P6603The predictive role of T786C single nucleotide polymorphism in endothelial no-synthase gene in late left ventricular remodeling after ST-segment elevation myocardial infarction
  125. Impaired function of fibroblast growth factor 23 / Klotho protein axis in prediabetes and diabetes mellitus: Promising predictor of cardiovascular risk
  126. Circulating platelet-derived vesicle in atrial fibrillation
  127. Altered signature of apoptotic endothelial cell-derived microvesicles predicts chronic heart failure phenotypes
  128. Platelet-derived vesicles: diagnostic and predictive value in cardiovascular diseases
  129. Platelet-Derived Vesicles in Hypertension: New Target for Risk Stratification?
  130. Vascular Access Surgery - Tips and Tricks
  131. Endothelial Progenitor Cells: Novel Biological Marker for Risk Stratification in Arterial Hypertension?
  132. Circulating vascular endothelial growth factor in ST-segment elevation myocardial infarction: from bench to bedside
  133. Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers
  134. Dynamic changes of circulating vascular endothelial growth factor levels in ST-segment elevation myocardial infarction: Controversies in clinical interpretation
  135. Endothelial progenitor cell dysfunction in diabetes mellitus: new target for risk stratification and therapies?
  136. Cellular care and extracellular vesicles therapies of heart failure
  137. Platelet-derived vesicles in acute myocardial infarction
  138. Endogenous vascular repair system in cardiovascular disease: The role of endothelial progenitor cells
  139. Soluble Suppression of Tumorigenicity 2: A Role in BiomarkerGuided Therapy of Heart Failure
  140. Терапевтический потенциал L-аргинина при кардиоваскулярных заболеваниях
  141. Elevated levels of circulating soluble ST2 at discharge predict late adverse ventricular remodeling in patients with ST-segment elevation myocardial infarction
  142. The endothelial progenitor cell dysfunction in hypertension: the diagnostic and predictive values
  143. Association of growth-differentiation factor-15 with the number of circulating proangiogenic endothelial progenitor cells in patients with type 2 diabetes mellitus
  144. Neutrophil extracellular traps: The core player in vascular complications of diabetes mellitus
  145. Emerging Role of Galectin-3 in Pulmonary Artery Hypertension
  146. Reply to: Is serum uric acid a pretty accurate prognostic predictor of ST elevated acute coronary syndrome? Author: Alexander E. Berezin
  147. Possible Role of Soluble St2 in Pulmonary Artery Hypertension
  148. Circulating biomarkers in heart failure: diagnostic and prognostic importance
  149. Stem Cells and Stem Cells / Precursors-Derived Extracellular Vesicles in Heart Failure: What is Better for Cardiac Regeneration?
  150. Is serum uric acid a pretty accurate prognostic predictor of ST elevated acute coronary syndrome?
  151. Effect of Thymol against Fungi Deteriorating Mural Paintings at Tell Basta Tombs, Lower Egypt
  152. Circulating Biomarkers in Heart Failure
  153. The role of progenitor endothelial cell dysfunction in arterial hypertension
  154. Can C-reactive Protein Genetic Variants Identify Patients with Higher and Lower Cardiovascular Risk?
  155. Is Galectin-3 a Prognosticator of Severity and Clinical Outcomes of Pulmonary Artery Hypertension?
  156. The endothelial progenitor cell dysfunction in type 2 diabetes mellitus: the link with heart failure developing
  157. The Endothelial Progenitor Cell Dysfunction in Type 2 Diabetes Mellitus: The Link with Heart Failure Developing
  158. Progenitor Endothelial Cells in Pulmonary Arterial Hypertension
  159. Challenging role of neutrophil extracellular traps in vascular complications of diabetes mellitus
  160. The Impact of Endothelial Progenitor Cell Dysfunction in Heart Failure “Obesity Paradox”
  161. The Impact of Endothelial Progenitor Cell Dysfunction in Heart Failure “Obesity Paradox”
  162. The obesity phenotypes: emerging role of cardiac biomarkers
  163. Promising utilities of growth differentiation factor 15 in cardiovascular diseases
  164. Growth Differentiation Factor 15 As Promising Biomarker Of Poor Prognosis In Heart Failure
  165. Pattern of Micro Vesicles in Heart Failure: Novel Biomarker of Endothelial Dysfunction and Vascular Reparation
  166. Enterococcus faecium L-3 in Eradication of Helicobacter pylori: In-vivo and In-vitro
  167. Serum uric acid as a metabolic regulator of endothelial function in heart failure
  168. [BP.04.06] CIRCULATING ENDOTHELIAL-DERIVED APOPTOTIC MICROPARTICLES TO MONONUCLEAR PROGENITOR CELLS RATIO AS A PREDICTOR OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ACUTELY DECOMPENSATED HEART
  169. Dysfunction of Endothelial Cell Precursors in Heart Failure Development
  170. Uric Acid in Heart Failure: Controversy Factor in The Multiple Pathogenesis of The Disease
  171. P6493Non-classical phenotypes of circulating endothelial cell-derived progenitor cells predicts asymptomatic atherosclerosis metabolically unhealthy obesity
  172. Up-to-date clinical approaches of biomarkers’ use in heart failure
  173. 1314Endothelial progenitor cells and apoptotic endothelial cell-derived microparticle ratio predicts atrial fibrillation in chronic heart failure
  174. Abstracts
  175. Are inflammatory cytokines and angiogenic factors a predictive biomarker of diabetes retinopathy?
  176. The Controversial Role of Osteopontin in Vascular Calcification: From Bench to Bedside
  177. Abstract Book: ISEV2017
  178. Is advanced Coupling Methods best fitted in Biosensing of Microparticles?
  179. Biosensing of Circulating Apoptotic Endothelial Cell Micro particles: The Impact in Risk Stratification of Obesity
  180. Circulating apoptotic endothelial cell-derived microparticles are predicted metabolically unhealthy obesity
  181. The number of red blood cell-derived microparticles in predicting periprocedural adverse effects in acute STsegment elevation myocardial infarction patients
  182. Assessment of nephroprotective action of angiotensin-converting enzyme inhibitor ramipril in patients with chronic glomerulonephritis
  183. Biosensing of periprocedural events in acute ST-segment elevation myocardial infarction patients with the erythrocyte-derived microparticles
  184. "Obesity Paradox" in Heart Failure: The Possible Role of Progenitor Endothelial Cell Dysfunction
  185. Microparticles in Chronic Heart Failure
  186. The predictive value of circulating apoptotic endothelial cell-derived micro particles in obesity progression?
  187. Number of Circulating Endothelial Progenitor Cells as a Predictive Biomarker of Heart Failure
  188. The Growth/Differentiation Factor-15 in Chronic Heart Failure: New Challenge in Biomarker-Guided Therapy?
  189. The Role of Vistafin in Diabetes-Induced Impairment of Endothelial Repair System
  190. The role of circulating endothelial progenitor cell dysfunction in pregnancy-induced hypertension
  191. Preconditioned Endothelial Progenitor Cells as Biomarker of Vascular Reparation?
  192. Novel Biomarkers in Prediction of Heart Failure Related Outcomes: From Bench to Bedside
  193. Current understanding of the role of new cardiac biomarkers in prediction of heart failure
  194. The placental cell-derived exosomes as a promising predictive biomarker of preeclampsia in symptomatic pregnancies
  195. Hypertension in Pregnancy: The Role of Circulating Endothelial Progenitor Cell Dysfunction
  196. Are Placental Cell-Derived Exosomes a Predictive Biomarker of Preeclampsia?
  197. Are Novel Cardiac Biomarkers Required in Prediction of Heart Failure Development and Outcomes?
  198. Could be Used an Immune Phenotypes of Circulating Endothelial Progenitor Cells as a Biomarker of Cardiovascular Disease?
  199. The Advanced Bright-field Light Optical Polarization Microscopy: Novel Coupling Method for Detection of Micro Vesicles
  200. Growth-Differentiation Factor-15 as Additional Prognostic Biomarkers in Heart Failure
  201. The Controversial Role of Serum Uric Acid in Cardiovascular Diseases
  202. The Endothelial Progenitor Cell Dysfunction: The Missed Predictor of Heart Failure Outcomes?
  203. Novel Biomarkers for Cardiovascular Risk in Obese Patients
  204. Combined methods for micro particles determining: are they useful?
  205. Osteopontin in Vascular Calcification: A Central Player or Accidental Witness?
  206. Coupling Analytical Methods for Detection of Microparticles: The Possibilities for Improvement
  207. Preconditioned Endothelial Progenitor Cells as Biomarker of Vascular Reparation?
  208. Progenitor Cell Dysfunction: The Role of Endothelial Precursors in Heart Failure
  209. Endothelial Repair and Endothelial Cell-Derived Secretome
  210. Biomarkers in Heart Failure
  211. Biosensing of red blood cell-derived extracellular vesicles with the advanced bright-field light optical polarization microscopy
  212. Bone-Related Proteins as Markers in Vascular Remodeling
  213. New Trends in Stem Cell Transplantation in Diabetes Mellitus Type I and Type II
  214. Novel Biomarkers at Risk Stratification of Diabetes Mellitus Patients
  215. The Advanced Bright-field Light Optical Polarization Microscopy: Novel Coupling Method for Detection of Micro Vesicles
  216. The altered vascular reparation in heart failure: the controversial role of endothelial progenitor cell dysfunction
  217. Epigenetics in heart failure phenotypes
  218. Cardiac biomarkers in diabetes mellitus: New dawn for risk stratification?
  219. An association of serum vistafin level and number of circulating endothelial progenitor cells in type 2 diabetes mellitus patients
  220. Acute Cardiovascular Care 2016
  221. Biomarkers for cardiovascular risk in patients with diabetes
  222. Links Between Concentrations of Serum 25-hydroxyvitamin D3 and the Numbers of Circulating Progenitor Mononuclear Cells in Patients With Metabolic Syndrome
  223. Endothelial progenitor cells dysfunction and impaired tissue reparation: The missed link in diabetes mellitus development
  224. Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients?
  225. Poster session 2Morphogenetic mechanisms290MiR-133 regulates retinoic acid pathway during early cardiac chamber specification291Bmp2 regulates atrial differentiation through miR-130 during early heart looping formationDevelopmental genetics294Associati...
  226. Data regarding association between serum osteoprotegerin level, numerous of circulating endothelial- derived and mononuclear-derived progenitor cells in patients with metabolic syndrome
  227. PS105 Impaired Immune Phenotype of Circulating Endothelial-Derived Microparticles in None-Diabetic Patients with Chronic Heart Failure
  228. Is the neutrophil extracellular trap-driven microvascular inflammation essential for diabetes vasculopathy?
  229. Abstracts
  230. Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives
  231. EuroHeartCare 2016
  232. Relation of osteoprotegerin level and numerous of circulating progenitor mononuclears in patients with metabolic syndrome
  233. Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction
  234. Circulating thrombospondin-2 in patients with moderate-to-severe chronic heart failure due to coronary artery disease
  235. The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis
  236. Contributors
  237. The Neutrophil Extracellular Traps: The Missed Link between Microvascular Inflammation and Diabetes?
  238. Pattern of circulating endothelial-derived microparticles among chronic heart failure patients with dysmetabolic comorbidities: The impact of subclinical hypothyroidism
  239. Impaired Immune Phenotype of Endothelial Cell-derived Micro Particles: The Missing Link between Diabetes-related States and Risk of Cardiovascular Complications?
  240. The Role of Circulating Myeloid-Related Protein Complex Calprotectin in Prediction of Heart Failure with Preserved Ejection Fraction
  241. The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus
  242. The Biomarker Utility in Risk Stratification in an Ambulatory Heart Failure: ST2 or Galectin-3?
  243. Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers
  244. Aortic Stenosis: Predictive Value of Cardiac Biomarkers in Older Patients
  245. Does Visfatin Predict Cardiovascular Complications in Metabolic Syndrome Patients?
  246. Extracellular vesicles as novel delivery drug system in heart failure: from bench to bedside?
  247. Elevated galectin-3 level predicts pulmonary artery hypertension
  248. Molecular and biochemical mechanisms of mitochondrial dysfunction in spontaneously hypertensive rats
  249. Predictive value of vistafin in metabolic syndrome patients: focus on cardiovascular complications
  250. Single sample and serial measurements of osteoprotegerin level as a target of therapy in type 2 diabetes mellitus?
  251. Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure
  252. Determination of early tumoricidal drug-induced cardiotoxicity with biological markers
  253. Can Osteoprotegerin be a Target of Therapy in Type 2 Diabetes Mellitus?
  254. Non-Classical Progenitor Mononuclears in Metabolic Syndrome: The Role of Serum 25-Hydroxyvitamin D3
  255. Impaired Pattern of Endothelial Cell-Derived Microparticles in Heart Failure Patients with Preserved and Reduced Left Ventricular Ejection Fraction
  256. Progenitor Endothelial Cell Dysfunction in Heart Failure: Clinical Implication and Therapeutic Target?
  257. Utilization of Novel Delivery Drug Systems Based on Release of Extracellular Vesicles in Heart Failure
  258. Global Longitudinal Strain and Strain Rate in Type Two Diabetes Patients with Chronic Heart Failure: Relevance to Osteoprotegerin
  259. Genetic Predictive Scores in Heart Failure: Possibilities and Expectations
  260. Progenitor Endothelial Cell Dysfunction in Obese Patients: Possibilities for Cardiovascular Risk Prediction
  261. Altered endothelial reparation and diabetes-Induced endothelial progenitor cell dysfunction
  262. Are Epigenetic Features Essential in Advance of Heart Failure Phenotypes?
  263. Blood pressure measurement assistance and antihypertensive drug compliance in older patients
  264. Circulating Vascular Endothelial Growth Factor-1 in Cardiovascular Disease
  265. Endothelial Repair in Diabetes: The Causative Role of Progenitor Cells Dysfunction?
  266. Epigenetic Mechanisms of Endothelial Progenitor Cell Dysfunction
  267. Epigenetic Modifications the Development of Different Heart Failure Phenotypes
  268. Epigenetically Modified Endothelial Progenitor Cells in Heart Failure
  269. Is Elevated Circulating Galectin-3 Level A Predictor of Pulmonary Artery Hypertension Development and Progression?
  270. Serum cystatin C and neutrophil gelatinase-associated lipocalin as biomarkers of glomerular and tubular kidney damage in patients with chronic glomerulonephritis and saved renal function
  271. Serum interleukin-18 as a biomarker of tubular kidney damage in patients with chronic glomerulonephritis
  272. The Cell-Free Mitochondrial DNA: A Novel Biomarker of Cardiovascular Risk?
  273. The Clinical Utility of Circulating Microparticles’ Measurement in Heart Failure Patients
  274. Endothelial Progenitor Cell Dysfunction as a Biomarker of Cardiovascular Risk in Obese Patients
  275. Different Obese Phenotypes and Progenitor Endothelial Cell Dysfunction: The Missed Link to Cardiovascular Risk
  276. Utility of the Red Blood Cell-Derived Microparticles as a Marker of Periprocedural Adverse Effects amongst Patients with Acute ST-Segment Elevation Myocardial Infarction
  277. The Endothelial Cell Secretome as a Factor of Endothelium Reparation: The Role of Microparticles
  278. The Promises, Methodological Discrepancies and Pitfalls in Measurement of Cell-Derived Extracellular Vesicles in Diseases
  279. The approaches to none-invasive detection of cell-derived extracellular vesicles
  280. The heart failure risk predictive scores based on the genetic features: hope and hype
  281. The risk stratification in heart failure patients: The controversial role of high-sensitive ST2
  282. The signature of circulating microparticles in heart failure patients with metabolic syndrome
  283. Biomarker-Guided Therapy for Chronic Heart Failure
  284. Endothelial progenitor cell-mediated vascular repair system in diabetes
  285. C-Reactive Protein and Complements as an Acute Phase Response after Cardiac Surgery
  286. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation
  287. Predictive value of circulating osteonectin in patients with ischemic symptomatic chronic heart failure
  288. Novel biomerker-based score for heart failure
  289. Predictive Value of Circulatingve-catherin in Coronary Artery Disease Patients with Symptomatic Moderate to Severe Chronic Heart Failure
  290. Stable Coronary Artery Disease Patients: Different Practice Patterns in Everyday Clinical Situations
  291. Endothelial Derived Micro Particles: Biomarkers for Heart Failure Diagnosis and Management
  292. Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15
  293. Impaired phenotype of circulating endothelial microparticles in chronic heart failure patients: Relevance to body mass index
  294. The effect of angiotensin-2 receptor blocker valsartan on circulating level of endothelial progenitor cells in diabetic patients with asymptomatic coronary artery disease
  295. The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients
  296. The Impact of Low-Grading Inflammation on Circulating Endothelial-Derived Progenitor Cells in Patients with Metabolic Syndrome and Diabetes Mellitus
  297. Impaired Immune Phenotype of Circulating Endothelial-Derived Microparticles in None-Diabetic Patients with Chronic Heart Failure: Impact on Insulin Resistance
  298. The predictive role of circulating microparticles in patients with chronic heart failure
  299. Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases
  300. [PP.36.09]
  301. [PP.36.08]
  302. Moderated Poster Session 2: Sunday 3 May 2015, 15:30-16:30 * Room: Moderated Poster Area
  303. Poster Session 2: Monday 4 May 2015, 08:00-18:00 * Room: Poster Area
  304. Poster Session 3: Tuesday 5 May 2015, 08:30-12:30 * Room: Poster Area
  305. Predictive value of apoptotic microparticles to mononuclear progenitor cells ratio in advanced chronic heart failure patients
  306. Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus
  307. Rational Synthesis of AB-Type N -Substituted Core-Functionalized Naphthalene Diimides (cNDIs)
  308. Содержание циркулирующих эндотелиальных прогениторных клеток у пациентов с хронической сердечной недостаточностью ишемической природы с сохраненной фракцией выброса левого желудочка
  309. Circulating Vascular Endothelial Growth Factor-1 in Cardiovascular Disease
  310. The association of serum osteoprotegerin/ sRANKL complex, C-reactive protein and adiponectin with number of circulating endothelial progenitor cells in patients with metabolic syndrome and diabetes mellitus
  311. The Role of Cardiac Biomarkers in Predicting of Mortality in Diabetic Patients
  312. The Development of Biological Molecular Sensing Techniques to detect Micro particles: Focus on Clinical Medicine Benefits
  313. Complications of Pharmacological Spasm Provocation Tests
  314. The Interplay of Aging, Aortic Stiffness and Blood Viscosity in Atherogenesis
  315. Transluminal endovascular aortic repair and pregnancy: a case report
  316. Inflammatory phenotype of circulating endothelial-derived microparticles in chronic heart failure patients with metabolic syndrome
  317. Micro RNA as Biomarkers and Tool for Target-Based Treatment in Patients with Inflammatory Bowel Diseases
  318. Immune Phenotypes of Endothelial-Derived Microparticles in Dysmetabolic Patients.
  319. Immune Phenotype of Circulating Endothelial-derived Microparticlesin Elderly Patients with Metabolic Syndrome and Diabetes Mellitus
  320. Vascular Endothelial Growth Factor-1 Level and Functional Neurologic Recovery after Ischemic Hemispheric Stroke
  321. The Metabolic Effects of Mineralocorticoid Receptor Antagonists in Heart Failure Patients
  322. Prognostication of heart failure development and advance: the role of high-sensitive ST2
  323. Impaired Phenotype of Circulating Endothelial-Derived Microparticles: Novel Marker of Cardiovascular Risk
  324. Circulating Cell-Free Mitochondrial DNA as Biomarker of Cardiovascular risk: New Challenges of Old Findings
  325. Biomarker-Guided Therapy for Chronic Heart Failure
  326. Bone-Related Proteins as Markers in Vascular Remodeling
  327. Utility of Biomarkers in Contemporary Management of Chronic Heart Failure
  328. Cardiovascular Biomarkers in Routine Screening of Diabetic Pati ents
  329. Early tumoricidal drug-induced cardiotoxicity determination: possibilities of biological markers
  330. The Pattern of Circulating Microparticles in Diabetes Mellitus Patients with Known Subclinical Atherosclerosis
  331. Signature of circulating endothelial-derived progenitor cells in patients with metabolic syndrome and diabetes mellitus
  332. Cell therapy of chronic heart failure: perspective of clinical approach
  333. The fixed combination of aliskiren and nebivolol in hypertensive patients: the clinical perspectives
  334. Impact of age on pattern of circulating endothelial-derived microparticles in heart failure patients
  335. Predictive Value of Circulating SPARC-Related protein Osteonectin in Patients with Symptomatic Moderate-to-Severe Ischemic-Induced Chronic Heart Failure
  336. The relationship between serum uric acid level and concentration of proangiogenic mononuclear progenitor cells in patients with chronic heart failure
  337. Relationship between circulating endothelial progenitor cells and insulin resistance in non-diabetic patients with ischemic chronic heart failure
  338. P202Interrelationship between circulating osteoprotegerin and subclinical coronary atherosclerosis in patients with type two diabetes mellitus
  339. P194Serum uric acid as independent predictor of decreased number of circulating proangiogenic progenitor cells in asymptomatic coronary artery disease patients
  340. Circulating Endothelial Progenitor Cells as Markers for Severity of Ischemic Chronic Heart Failure
  341. Impaired Pattern of Endothelial Derived Microparticles in Heart Failure Patients
  342. Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives
  343. Serum Uric Acid Predicts Declining of Circulating Proangiogenic Mononuclear Progenitor Cells in Chronic Heart Failure Patients
  344. Serum Rankl/Osteoprotegerin Complex and Endothelial Progenitor Cells in Chronic Heart Failure
  345. Predictive Value of Circulating Vascular Endothelial Growth Factor-1 Level Measured Repeatedly During Long-Term Follow-Up in Patients with Arterial Hypertension after Acute Ischemic Stroke
  346. Predictive Value of Circulating Apoptotic Microparticles in Patients with Ischemic Symptomatic Moderate-To-Severe Chronic Heart Failure
  347. Apoptotic Microparticles as Predicted Biomarkers in Patients with Chronic Heart Failure – Relevance to Inflammatory Cytokines and Outcomes
  348. C-reactive protein after stroke in arterial hypertension
  349. Vascular endothelial growth factor-1 as a predictor of unfavorable cardiovascular events in arterial hypertension patients after ischemic stroke
  350. Relationship between level of circulating endothelial progenitor cells and severity of ischemic chronic heart failure with preserved left ventricular ejection fraction
  351. Predict value of circulating bone-related glycopeptide osteoprotegerin in asymptomatic coronary artery disease patients with second type diabetes mellitus
  352. Predict value of circulating endothelial progenitor cells in patients with moderate-to-severe chronic heart failure due to coronary artery disease
  353. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease
  354. Analysis of Various Subsets of Circulating Mononuclear Cells in Asymptomatic Coronary Artery Disease
  355. Oral Abstract Session: Novel non-invasive risk marker
  356. Prognostic value of biological markers in myocardial infarction patients
  357. Circulating endothelial progenitor cells as a predictor of clinical outcomes in diabetic patients with symptomatic chronic heart failure
  358. A potential predict value of circulating osteoprotegerin in diabetic patients with asymptomatic coronary artery disease
  359. Serum Uric Acid as a Marker of Coronary Calcification in Patients with Asymptomatic Coronary Artery Disease with Preserved Left Ventricular Pump Function
  360. Predictive Value of Circulating Vascular Endothelial Growth Factor-1 in Arterial Hypertension Patients
  361. Bone-related circulating proteins as early predictors of coronary atherosclerosis in asymptomatic patients with known coronary artery disease
  362. Neuroprotective and memory enhancing properties of a dual agonist of the FGF receptor and NCAM
  363. Poster session 1
  364. Poster session 3
  365. TRANSFORMING GROWTH FACTOR-BETA 1 AND HEART REMODELING IN TYPE 2 DIABETES MELLITUS PATIENTS ASSOCIATED WITH LEFT VENTRICULAR DIASTOLIC DYSFUNCTION
  366. SIMVASTATIN IN ESCALATION DOSES IMPROVE RENAL FUNCTION IN PATIENTS WITH DIABETES MELLITUS AND MILD-TO-MODERATE PROTEINURIA
  367. OSTEOPONTIN PLASMA LEVEL AS A TARGET IN THE ASSESSMENT OF SEVERITY HEART FAILURE AND CARDIAC REMODELLING
  368. CIRCULATING STROMELYSIN-1 AS A POSSIBLE MARKER OF SEVERITY OF CARDIOVASCULAR REMODELING IN OBESITY PATIENTS AFTER MYOCARDIAL INFARCTION
  369. Abstracts
  370. Abstracts
  371. Saturday, 17 July 2010
  372. Candesartan cilexitil reduces neurohumoral and proinflammatory activation in patients with severe congestive heart failure
  373. 774 Highly selective beta-1 blocker bisoprolol significantly improves long-term prognosis in asymptomatic heart failure patients
  374. 724 Low doses of statins improve neurohumoral activity in patients with moderate-to-severe congestive heart failure due to coronary artery disease
  375. 313 The interrelation between plasma level of natriuretic peptide and long-term prognosis about patients with congestive heart failure
  376. 166 Angiotensin-2 receptor blockade with losartan improves left ventricular function at rest and post-exercise in heart failure patients with preserved ejection fraction
  377. 470 Angiotensin-2 receptor blockade with losartan improves left ventricular function at rest and post-exercise in heart failure patients with preserved ejection fraction
  378. Losartan in the Therapy of Heart Failure Patients
  379. 4.11 The interrelation between plasma level of atrial natriuretic peptide and long-term prognosis about patients with congestive heart failure
  380. 4.10 Long-term administration of angiotensin-2 receptor antagonist losartan adding to ace inhibitor enalapril in patients with congestive heart failure
  381. The dose-dependent influence of angiotensin-II receptor antagonist losartan on remodeling and neurohumoral status in patients with congestive heart failure
  382. Angiotensin-II receptor antagonist losartan improves the diastolic performance in patients with asymptomatic heart failure due to myocardial infarction
  383. Biological Markers and Guided Therapy